Lightstone Ventures invests in early-stage life science companies, focusing on breakthrough therapeutics and medical technologies that have the potential to significantly change patient outcomes.
About Lightstone Ventures
Lightstone Ventures is a Boston- and Bay Area-anchored healthcare venture firm investing across biotech, medical devices, and digital health, with the resources and clinical operator depth typical of a multi-stage life-sciences fund. Stage focus runs from Series A through later rounds, with checks plausibly in the $5M to $25M range and full reserves for follow-on participation. Founders building therapeutic assets, novel medical devices with a defined regulatory pathway, and digital health platforms with a credible reimbursement strategy are the right profile. Physician founders should expect rigorous diligence on clinical evidence, IP, and the regulatory plan; this is not a fund that will accept a software-style pitch with hand-waved health context. Wholly consumer wellness, brand-led DTC, or pure-play SaaS without clinical anchoring will not resonate. Geographic posture is US-led with comfortable transatlantic deals. Entry is best through warm introduction from a clinician-investor, an academic medical center commercialization office, or a partner at a co-investing seed firm; the partners are accessible at industry conferences such as JPM and AdvaMed. Founders should bring KOL endorsements, clean preclinical or clinical data, and a defensible commercial plan, then expect a quiet, professional process. Treat Lightstone as a serious lead investor for capital-intensive healthcare companies that have moved past the proof-of-concept stage and are ready to fund pivotal studies, regulatory submissions, or commercial scaling under disciplined oversight.
Founder reviews
Other portfolio companies
Companies in Lightstone Ventures's portfolio not currently in our directory.
Team
Pitch / review this investor
Have you raised from Lightstone Ventures? Founders only — share your honest experience (anonymous OK, moderated before publishing).